Craig C. Hopkinson
Net Worth

Last updated:

What is Craig C. Hopkinson net worth?

The estimated net worth of Dr. Craig C. Hopkinson is at least $14,243,590 as of 9 Dec 2024. He owns shares worth $1,379,704 as insider, has earned $5,723,886 from insider trading and has received compensation worth at least $7,140,000 in Alkermes plc.

What is the salary of Craig C. Hopkinson?

Dr. Craig C. Hopkinson salary is $1,020,000 per year as Executive Vice President of R&D and Chief Medical Officer in Alkermes plc.

How old is Craig C. Hopkinson?

Dr. Craig C. Hopkinson is 57 years old, born in 1968.

What stocks does Craig C. Hopkinson currently own?

As insider, Dr. Craig C. Hopkinson owns shares in one company:

Company Title Shares Price per share Total value
Alkermes plc (ALKS) Executive Vice President of R&D and Chief Medical Officer 47,576 $29 $1,379,704

What does Alkermes plc do?

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS logo
ALKS
Alkermes plc
$29

Craig C. Hopkinson insider trading

Alkermes plc

Dr. Craig C. Hopkinson has made 9 insider trades between 2018-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 61,151 units of ALKS stock on 9 Dec 2024. As of 9 Dec 2024 he still owns at least 47,576 units of ALKS stock.

Transaction Date Security Shares Price per share Total value Source
Option
Ordinary Shares 12,411 $26.82 $332,863
Option
Ordinary Shares 12,452 $20.03 $249,414
Sale
Ordinary Shares 61,151 $32.08 $1,961,418
Option
Ordinary Shares 12,090 $19.34 $233,821
Option
Employee Stock Option (Right to Buy) 12,090 $19.34 $233,821
Option
Employee Stock Option (Right to Buy) 12,044 $24.59 $296,162
Option
Ordinary Shares 12,044 $24.59 $296,162
Option
Employee Stock Option (Right to Buy) 12,452 $20.03 $249,414
Option
Employee Stock Option (Right to Buy) 12,411 $26.82 $332,863
Sale
Ordinary Shares 9,221 $31.5 $290,462
Sale
Ordinary Shares 14,349 $30.77 $441,547
Option
Ordinary Shares 43,058 $20.03 $862,452
Sale
Ordinary Shares 58,996 $30.08 $1,774,600
Option
Employee Stock Option (Right to Buy) 43,058 $20.03 $862,452
Sale
Ordinary Shares 10,471 $29.53 $309,167
Option
Restricted Stock Unit Award 7,689 N/A N/A
Option
Ordinary Shares 7,689 N/A N/A
Option
Ordinary Shares 12,278 N/A N/A
Option
Restricted Stock Unit Award 12,278 N/A N/A
Option
Restricted Stock Unit Award 12,038 N/A N/A
Option
Ordinary Shares 12,038 N/A N/A
Option
Ordinary Shares 6,875 N/A N/A
Option
Restricted Stock Unit Award 6,875 N/A N/A
Option
Ordinary Shares 10,095 N/A N/A
Option
Restricted Stock Unit Award 10,095 N/A N/A
Option
Restricted Stock Unit Award 8,722 N/A N/A
Option
Ordinary Shares 8,722 N/A N/A
Sale
Ordinary Shares 11,983 $24.76 $296,651
Option
Restricted Stock Unit Award 10,096 N/A N/A
Option
Restricted Stock Unit Award 6,875 N/A N/A
Option
Ordinary Shares 12,037 N/A N/A
Option
Restricted Stock Unit Award 12,037 N/A N/A
Option
Ordinary Shares 6,875 N/A N/A
Option
Ordinary Shares 10,096 N/A N/A
Sale
Ordinary Shares 2,306 $25.17 $58,042
Option
Restricted Stock Unit Award 3,375 N/A N/A
Option
Ordinary Shares 3,375 N/A N/A
Sale
Ordinary Shares 882 $24.6 $21,697
Option
Restricted Stock Unit Award 1,250 N/A N/A
Option
Ordinary Shares 1,250 N/A N/A
Sale
Ordinary Shares 28,920 $19.72 $570,302
Option
Restricted Stock Unit Award 6,875 N/A N/A
Option
Ordinary Shares 6,875 N/A N/A
Option
Restricted Stock Unit Award 10,095 N/A N/A
Option
Ordinary Shares 10,095 N/A N/A
Option
Ordinary Shares 3,375 N/A N/A
Option
Restricted Stock Unit Award 3,375 N/A N/A
Option
Ordinary Shares 1,250 N/A N/A
Option
Restricted Stock Unit Award 1,250 N/A N/A
Option
Ordinary Shares 6,875 N/A N/A
Option
Employee Stock Option (Right to Buy) 6,875 N/A N/A
Option
Restricted Stock Unit Award 6,875 N/A N/A
Option
Ordinary Shares 3,375 N/A N/A
Option
Restricted Stock Unit Award 3,375 N/A N/A
Option
Ordinary Shares 1,250 N/A N/A
Option
Restricted Stock Unit Award 1,250 N/A N/A
Option
Ordinary Shares 3,375 N/A N/A
Option
Restricted Stock Unit Award 3,375 N/A N/A
Option
Restricted Stock Unit Award 1,250 N/A N/A
Option
Ordinary Shares 1,250 N/A N/A

Alkermes key executives

Alkermes plc executives and other stock owners filed with the SEC: